Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction

Chronic Total Occlusion of Coronary Artery Clinical Trial

— REVISE-CTO  

Official title:

REvascularization Versus Optimal Medical Therapy on Left Ventricular ISchemia Reduction: Exploring the Associations Between Ischemia, Functional Outcome and Collaterals in the Treatment of Chronic Total Occlusion Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03756870
• Other study ID #: REVISE-CTO
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2019
• Est. completion date: January 1, 2030

Study information

• Verified date: July 2023
• Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Contact: Prof. J.P.S. Henriques, MD PhD
• Phone: +31205666405
• Email: j.p.henriques[@]amc.uva.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale: Randomized trials could not yet establish favourable outcomes of CTO PCI on hard endpoints such as ejection fraction or mortality, when compared to optimal medical therapy. However, patients after CTO PCI appeared to be more frequently free of angina complaints, but the aetiology behind this is not fully understood. The investigators hypothesize that PCI of the CTO in patients preselected with an ischemic threshold (>12.5%) on cardiac imaging leads to a reduction of the ischemic burden and therefore an increased benefit on functional outcomes.

Objective: Primary objective is to determine whether PCI of the CTO will yield a higher reduction of ischemia assessed by exercise myocardial perfusion SPECT-CT from baseline to 6-month follow-up compared to a control group. Secondary objectives are 1) to evaluate the effect of PCI of the CTO on improvement in functional status, infarct size and left ventricular function from baseline to follow-up compared to the control group; 2) to study the association between ischemia reduction and functional outcome and left ventricular function; 3) to assess the influence of the collateral flow index on the ischemic burden (reduction), functional status, infarct size and left ventricular (contractile) function (hibernation).

Study design: open multicentre randomized trial

Study population: 82 patients eligible for CTO PCI

Intervention: CTO PCI

Primary endpoint: ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: January 1, 2030
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. A chronic total occlusion is present and target lesion. A CTO is required to meet the following characteristics:

• A 100% luminal narrowing of the coronary artery without antegrade flow, i.e. Thrombolysis in Myocardial Infarction flow grade 0 or 1;

• Older than 3 months, established with previous PCI or with angiographic characteristics;

• Amenable to percutaneous revascularization.

2. Patient has a clinical indication to perform CTO PCI.

3. A SPECT is performed at baseline to assess ischemia and a cardiac magnetic resonance imaging (CMR) scan to assess viability, as part of routine patient care. Patients are deemed eligible for the randomized trial when they meet the ischemic threshold in the CTO territory.

The ischemic threshold is defined as:

• >12.5% of ischemia;

• With <50% transmural extent of infarction.

4. Subject agrees to undergo follow-up SPECT-CT at 6 months after initial inclusion

5. Subject is able to verbally confirm understanding and he/she provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.

Exclusion Criteria:

• Subject is younger than 18 years of age;

• Persistent or permanent atrial fibrillation;

• Presence of a non-MRI compatible cardiac device, i.e. pacemaker or implantable cardioverter defibrillator;

• Body weight > 250 kg;

• Unable to exert, i.e. due to physical disability;

• Any contraindication for SPECT or CMR, i.e. cerebrovascular clips, claustrophobia;

• Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] <60 mL/min/1.73m2 or serum creatinine level of >2.5 mg/dL or subject on dialysis);

• Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;

• Presence of a comorbid condition with a life expectancy of less than one year;

• Participation in another trial;

• Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.

Related Conditions & MeSH terms

• Chronic Total Occlusion of Coronary Artery
• Coronary Occlusion
• Ischemia

Intervention

Procedure:
• Percutaneous coronary intervention (PCI)
A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.

Locations

Country	Name	City	State
Netherlands	Amsterdam UMC, location AMC	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ischemia	Ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.	6 months follow-up
Secondary	Change in angina status assessed with the Seattle Angina Questionnaire.	5 Seattle Angina Questionnaire subscales (0-100), higher scores indicating better angina status.	6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years
Secondary	Quality of life assessed with the Minnesota Living with Heart Failure Questionnaire (MLHFQ)	MLHFQ scale (0-105), lower scores indicating better quality of life.	6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years
Secondary	The left ventricular ejection fraction assessed with cardiac magnetic resonance imaging		6 months